Biogen (NASDAQ:BIIB) shares have seen a variation of ups and downs with a stock price rise of
3.5%, due to predictions by analysts claiming the company's stocks will skyrocket. Despite suffering a hit after its Earnings Report, significant positions were taken by multiple investment firms.
Leqembi, a potential treatment for early Alzheimer's disease has gained regulatory reception from the FDA and positive ratings from EU regulatory bodies, potentially benefiting 22 million patients. However, advisory in the EU have dampened the share value. The company is also expecting a profit decline for 2025 despite strong Q4 results. Possible future growth is expected from the integration of Leqembi and Skyclarys, according to analysts. Biogen also added
Tim Power as Head of Investor relations who is set to strengthen the growing influence of the firm. The company made a proposal to acquire Sage Therapeutics which was rejected, describing the offer undervalues the company. Furthermore, partnerships have been formed with Stoke Therapeutics, UCB, Sage Therapeutics, and an acquisition of Human Immunology Biosciences. Biogen remains a popular choice amongst analysts and investors despite mixed sentiments.
Biogen BIIB News Analytics from Thu, 16 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 11:02:38 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -4
